CD163 and rheumatoid arthritis: In the group of RA patients who were not treated with bDMARDs, the ratio of CD14++CD80+/CD14++CD163+ from both the IFP and SC was as high as 0.79 (0.65–0.90) and 0.86 (0.43–0.98) (Figure 3B).